{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:38:53Z","timestamp":1790246333736,"version":"4.1.0"},"reference-count":49,"publisher":"Tottori University Faculty of Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Yonago Acta Med."],"published-print":{"date-parts":[[2019]]},"DOI":"10.33160\/yam.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:05:23Z","timestamp":1553709923000},"page":"001-007","source":"Crossref","is-referenced-by-count":2,"title":["Turning Point in the Treatment of Mantle Cell Lymphoma"],"prefix":"10.33160","volume":"62","author":[{"given":"Toru","family":"Motokura","sequence":"first","affiliation":[{"name":"Division of Clinical Laboratory Medicine, Department of Pathophysiological and Therapeutic Science, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18656","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89:3909-18. PMID: 9166827","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2 Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al.Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536-45. doi:10.1111\/bjh.12659 PMID: 24245986 PMCID: PMC3907701","DOI":"10.1111\/bjh.12659"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Raffeld M, Jaffe ES.bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259-63. PMID: 2070063","DOI":"10.1182\/blood.V78.2.259.bloodjournal782259"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, et al.A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 1991;350:512-5. doi:10.1038\/350512a0 PMID: 1826542","DOI":"10.1038\/350512a0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, et al.Mantle cell lymphoma, a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992;16:637-40. PMID: 1530105","DOI":"10.1097\/00000478-199207000-00001"},{"key":"6","unstructured":"6 Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL.Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol. 1994;145:86-96. PMID: 7518196 PMCID: PMC1887308"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7 Smith A, Roman E, Appleton S, Howell D, Johnson R, Burton C, et al.Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK\u2019s Haematological Malignancy Research Network (HMRN). Br J Haematol. 2018;181:215-28. doi:10.1111\/bjh.15170 PMID: 29532919","DOI":"10.1111\/bjh.15170"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al.A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-65. PMID: 17962512","DOI":"10.1182\/blood-2007-06-095331"},{"key":"9","unstructured":"9 Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, et al.Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: Results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016;34:1386-94. doi:10.1200\/JCO.2015.63.8387PMID: 26926679"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Bottcher S, Asnafi V, et al.Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215-23. PMID: 20032498","DOI":"10.1182\/blood-2009-06-230250"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A, et al.Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315-21. doi:10.1182\/blood-2005-04-1753 PMID: 16123218 PMCID: PMC1895253","DOI":"10.1182\/blood-2005-04-1753"},{"key":"12","unstructured":"12 Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, et al.Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253-61. PMID: 10733493"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kobayashi H, Kitano K, Saito H, Aoki K, Narita A, Terada N, et al.Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). Cancer Genet Cytogenet. 1995;84:69-72. PMID: 7497446","DOI":"10.1016\/0165-4608(95)00083-6"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14 Ruchlemer R, Parry-Jones N, Brito-Babapulle V, Attolico I, Wotherspoon AC, Matutes E, et al.B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Haematol. 2004;125:330-6. doi:10.1111\/j.1365-2141.2004.04913.x PMID: 15086413","DOI":"10.1111\/j.1365-2141.2004.04913.x"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375-90. doi:10.1182\/blood-2016-01-643569 PMID: 26980727 PMCID: PMC4874220","DOI":"10.1182\/blood-2016-01-643569"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16 Jares P, Colomer D, Campo E.Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122:3416-23. doi:10.1172\/JCI61272 PMID: 23023712 PMCID: PMC3461905","DOI":"10.1172\/JCI61272"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR, et al.p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302-10. PMID: 8639789","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Zoldan MC, Inghirami G, Masuda Y, Vandekerckhove F, Raphael B, Amorosi E, et al.Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome. Br J Haematol. 1996;93:475-86. PMID: 8639452","DOI":"10.1046\/j.1365-2141.1996.5421085.x"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG, et al.Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997;89:1421-9. PMID: 9028966","DOI":"10.1182\/blood.V89.4.1421"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Chikatsu N, Nakamura Y, Sato H, Fujita T, Asano S, Motokura T, et al.p53 mutations and tetraploids under r- and K-selection. Oncogene. 2002;21:3043-9. doi10.1038\/sj.onc.1205413PMID: 12082535","DOI":"10.1038\/sj.onc.1205413"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21 Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, et al.Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016;172:80-8. doi:10.1111\/bjh.13796 PMID: 26648336 PMCID: PMC5471614","DOI":"10.1111\/bjh.13796"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22 Eskelund CW, Kolstad A, Jerkeman M, Raty R, Laurell A, Eloranta S, et al.15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016;175:410-8. doi:10.1111\/bjh.14241 PMID: 27378674","DOI":"10.1111\/bjh.14241"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23 Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, et al.Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565-75. doi:10.1016\/S0140-6736(16)00739-X PMID: 27313086","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, et al.Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250-60. doi:10.1056\/NEJMoa1701769 PMID: 28953447","DOI":"10.1056\/NEJMoa1701769"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25 Geisler CH, Kolstad A, Laurell A, Raty R, Jerkeman M, Eriksson M, et al.The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115:1530-3. doi:10.1182\/blood-2009-08-236570 PMID: 20032504","DOI":"10.1182\/blood-2009-08-236570"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al.TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903-10. doi:10.1182\/blood-2017-04-779736 PMID: 28819011","DOI":"10.1182\/blood-2017-04-779736"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27 Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al.Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-10. doi:10.1016\/S0140-6736(12)61763-2 PMID: 23433739","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28 Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al.Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123:2944-52. doi:10.1182\/blood-2013-11-531327 PMID: 24591201 PMCID: PMC4260975","DOI":"10.1182\/blood-2013-11-531327"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29 Chen RW, Li H, Bernstein SH, Kahwash S, Rimsza LM, Forman SJ, et al.RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol. 2017;176:759-69. doi:10.1111\/bjh.14480 PMID: 27992063 PMCID: PMC5318240","DOI":"10.1111\/bjh.14480"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30 Armand P, Redd R, Bsat J, Mayuram S, Giardino A, Fisher DC, et al.A phase 2 study of rituximab-bendamustine and rituximab-cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016;173:89-95. doi:10.1111\/bjh.13929 PMID: 26729345","DOI":"10.1111\/bjh.13929"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31 Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al.Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4:e15-e23. doi:10.1016\/S2352-3026(16)30185-5 PMID: 27927586","DOI":"10.1016\/S2352-3026(16)30185-5"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32 Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al.Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372:944-53. doi:10.1056\/NEJMoa1412096 PMID: 25738670","DOI":"10.1056\/NEJMoa1412096"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33 Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al.Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leuk Lymphoma. 2017;1-8. doi:10.1080\/10428194.2017.1321750 PMID: 28583031","DOI":"10.1080\/10428194.2017.1321750"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34 Solh M, Fisher RI, Goy A, de Vos S, Bernstein SH, Esseltine DL, et al.Herpes zoster complicating bortezomib therapy of relapsed\/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials. Leuk Lymphoma. 2013;54:2185-9. doi:10.3109\/10428194.2013.772294 PMID: 23383602","DOI":"10.3109\/10428194.2013.772294"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35 Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C, et al.Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol. 2012;23:1555-61. doi:10.1093\/annonc\/mdr450 PMID: 22012966","DOI":"10.1093\/annonc\/mdr450"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36 Romaguera JE, Wang M, Feng L, Fayad LE, Hagemeister F, McLaughlin P, et al.Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018;124:2561-9. doi:10.1002\/cncr.31361 PMID: 29723393","DOI":"10.1002\/cncr.31361"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37 Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S.Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res. 2013;37:1271-7. doi:10.1016\/j.leukres.2013.07.028 PMID: 23962569","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38 Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507-16. doi:10.1056\/NEJMoa1306220 PMID: 23782157 PMCID: PMC4513941","DOI":"10.1056\/NEJMoa1306220"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39 Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al.Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770-8. doi:10.1016\/S0140-6736(15)00667-4 PMID: 26673811","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40 Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, et al.Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412-24. doi:10.1182\/blood-2013-02-482125 PMID: 23940282 PMCID: PMC3790509","DOI":"10.1182\/blood-2013-02-482125"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41 Furtado M, Wang ML, Munneke B, McGreivy J, Beaupre DM, Rule S.Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. Br J Haematol. 2015;170:131-4. doi:10.1111\/bjh.13275 PMID: 25559624","DOI":"10.1111\/bjh.13275"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42 Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al.Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015;29:783-7. doi:10.1038\/leu.2014.247 PMID: 25138588","DOI":"10.1038\/leu.2014.247"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43 Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al.Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17:48-56. doi:10.1016\/S1470-2045(15)00438-6 PMID: 26640039","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44 Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al.Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014;123:1957-60. doi:10.1182\/blood-2014-01-547869 PMID: 24652965 PMCID: PMC3962169","DOI":"10.1182\/blood-2014-01-547869"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45 Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, et al.Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132:2016-25. doi:10.1182\/blood-2018-07-859769 PMID: 30181173","DOI":"10.1182\/blood-2018-07-859769"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46 Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al.Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211-23. doi:10.1056\/NEJMoa1715519 PMID: 29590547","DOI":"10.1056\/NEJMoa1715519"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47 Ogura M, Yamamoto K, Morishima Y, Wakabayashi M, Tobinai K, Ando K, et al.R-High-CHOP\/CHASER\/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Sci. 2018;109:2830-40. doi:10.1111\/cas.13719 PMID: 29957865 PMCID: PMC6125440","DOI":"10.1111\/cas.13719"},{"key":"48","doi-asserted-by":"publisher","unstructured":"48 Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, et al.VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: A Wisconsin Oncology Network Study. Clin Lymphoma Myeloma Leuk. 2018;18:e61-e7. doi:10.1016\/j.clml.2017.10.006 PMID: 29191715 PMCID: PMC5896779","DOI":"10.1016\/j.clml.2017.10.006"},{"key":"49","doi-asserted-by":"publisher","unstructured":"49 Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Shibayama H, et al.Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma. Cancer Sci. 2016;107:1785-90. doi:10.1111\/cas.13076 PMID: 27616553 PMCID: PMC5198949","DOI":"10.1111\/cas.13076"}],"container-title":["Yonago Acta Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/62\/1\/62_2019.03.001\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T05:42:31Z","timestamp":1574401351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/62\/1\/62_2019.03.001\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.33160\/yam.2019.03.001","relation":{},"ISSN":["1346-8049"],"issn-type":[{"value":"1346-8049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}